Scilex Holding (SCLX) Cash & Equivalents (QoQ) (2020 - 2026)
Scilex Holding (SCLX) Cash & Equivalents (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Scilex Holding | 39.22 Mn | -73.57 Mn | 3.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,823.77% |
| Dec 31, 2025 | 450.56% |
| Sep 30, 2025 | -78.04% |
| Jun 30, 2025 | -29.33% |
| Mar 31, 2025 | 77.26% |
| Dec 31, 2024 | 4,149.35% |
| Sep 30, 2024 | -98.88% |
| Jun 30, 2024 | 282.67% |
| Mar 31, 2024 | -54.09% |
| Dec 31, 2023 | 100.67% |
| Sep 30, 2023 | -94.27% |
| Jun 30, 2023 | 568.63% |
| Mar 31, 2023 | 133.52% |
| Dec 31, 2022 | 6,146.96% |
| Sep 30, 2022 | -90.05% |
| Jun 30, 2022 | 40.51% |
| Mar 31, 2022 | -94.24% |
| Dec 31, 2021 | 3,651.23% |
| Sep 30, 2021 | -55.11% |
| Jun 30, 2021 | -18.19% |